Zydus Lifesciences on Monday said it has received approval from the US health regulator to market generic medicines in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) to market Gabapentin tablets which are indicated for the management of postherpetic neuralgia (PHN).
As per IQVIA MAT data, the medication had annual sales of USD 90 million in the US.
The company said it also has received approval from the US health regulator for diabetes drug Canagliflozin and Metformin Hydrochloride tablets.
As per IQVIA MAT data, Canagliflozin and Metformin Hydrochloride tablets had annual sales of USD 49.4 million in the US.
Shares of the company on Monday ended 1.36 per cent down at Rs 464.15 apiece on the BSE.
Zydus Lifesciences Q2 net profit down 82.6% to Rs 523 cr on rising costs
Zydus gets USFDA nod to market generic medicine for treating depression
Zydus gets USFDA nod for generic version of Venlafaxine, Pregabalin
Zydus Lifesciences' generic drug for overactive bladder gets USFDA nod
Zydus Lifesciences US arm gets tentative USFDA nod for Sugammadex injection
You have disappeared like Mr India, says BJP to Uddhav on Mogambo jibe
Godhra train burning case: Gujarat govt seeks death penalty for 11 in SC
Indian Super League final to be played at Margao in Goa on March 18
Cereal prices likely to remain elevated going into next fiscal: CRISIL
NIA files 2nd additional chargesheet in Mundra Port narcotics seizure case
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)